Items Tagged ‘Halaven’

February 4th, 2016

Halaven Approved for Liposarcoma


The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven is already approved for the treatment of advanced breast cancer. The approval indication for Halaven in the treatment of […]

View full entry

Tags: eribulin, fda, Halaven, liposarcoma, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS

June 11th, 2015

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®


Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology.[1] Soft tissue sarcomas are cancers that affect the connective and supportive […]

View full entry

Tags: ADI, adipocytic sarcoma, Halaven, leiomyosarcoma, LMS, News, Sarcoma, soft tissue sarcoma, Soft Tissue Sarcomas, STS